Greater Munich Metropolitan Area
• Build and led a team for evaluation and development of innovative in vitro/ex vivo methods • Established high-throughput, automatable screening assays as well as translational mode-of-action experiments in line with regulatory quality standards, accelerating over 20 preclinical and clinical projects in immuno-oncology, inflammatory and respiratory diseases • Established an interactive workflow to mitigate risk of clinical immunogenicity during preclinical development • Technology and biomarker scouting for preclinical/translational research • Project leader of a preclinical immuno-oncology project (armored cell therapies) in 7 external research collaborations • Developed project plans, managed budget and resource allocation, guided project decision making • Presented at international conferences, identified and exchanged with business partners and supported due diligence
see above
• Scientifically led 3 preclinical immuno-oncology projects of bispecific proteins conducted in strategic partnerships with cross-functional teams to support successful development from early discovery to IND filing • Interpreted and oversaw all preclinical efficacy and non-clinical safety results, provided scientific expertise and contributed to project strategy • Managed external in vivo and non-clinical toxicological studies • Presented at international scientific conferences and engaged with KOLs • Prepared scientific reports and OPs, co-authored regulatory documents • Consulting on new therapeutic targets • Designed, executed and analyzed cell-based in vitro studies, providing technical guidance to Associate Scientists
• Preparation of a clinical phase I/II study on peptide-based anti-tumor vaccination for ovarian carcinomas • External communication and interaction with KOLs and collaboration partners • Validated and selected potential vaccine peptides • Coordinated individual therapeutic trials in collaboration with the University Women Hospital Tübingen • Immunomonitoring of individual therapeutic trials • Characterization of tumor-infiltrating T cells
Supervisors: Prof. Stefan Stevanovic and Prof. Hans-Georg Rammensee Thesis: Identification and characterization of naturally presented, immunogenic HLA ligands for establishing a peptide-based anti-tumor vaccination in ovarian cancer • Project coordination and supervision of undergraduate students • Designed, established and conducted immunological in vitro experiments, including T-cell priming, cloning and cytotoxicity as well as ELISPOT assays • Designed, performed and analyzed multicolor flow cytometry experiments and maintained flow cytometry devices • Conducted cell sorting (FACS and MACS), isolated and analyzed tumor-infiltrating T cells • Identified HLA ligands by immuno-affinity chromatography and mass spectrometry • Managed external collaborations and presented at international conferences
Internship to learn time-of-flight mass cytometry (CyTOF)
Supervisors: Assoc. Prof. Brigitte Gückel and Prof. Hans-Georg Rammensee Thesis: Charakterisierung neuer T-Zellepitope des Ovarialkarzinoms als Grundlage einer Peptid-basierten Immuntherapie.